{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:59:44Z","timestamp":1787950784268,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The identification of anti-NXP2 antibodies is considered a serological marker of dermatomyositis (DM), with calcinosis, severe myositis and, in some reports, with cancer. Historically, these associations with anti-NXP2 antibodies have been detected by immunoprecipitation (IP), but in the last few years commercial immunoblotting assays have been released. The aim of this collaborative project was to analyse the clinical features associated to anti-NXP2 antibodies, both with commercial line blot (LB) and IP. Myositis-specific and myositis-associated autoantibodies were detected in single centres by commercial line blot (LB); available sera were evaluated in a single centre by protein and RNA immunoprecipitation (IP), and IP-Western blot. Sixty patients anti-NXP2+\u2009(NXP2+) positive by LB were compared with 211 patients anti-NXP2 negative with idiopathic inflammatory myositis (IIM). NXP2+\u2009showed a younger age at IIM onset (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0014), more frequent diagnosis of dermatomyositis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026) and inclusion-body myositis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009), and lower rate of anti-synthetase syndrome (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). As for clinical features, NXP2+\u2009more frequently develop specific skin manifestations and less frequently features related with overlap myositis and anti-synthetase syndrome. IP confirmed NXP2 positivity in 31 of 52 available sera (62%). Most clinical associations were confirmed comparing NXP2 LB+\/IP+\u2009versus NXP2-negative myositis, with the following exceptions: inclusion-body myositis diagnosis was not detected, whilst dysphagia and myositis were found more frequently in NXP2 LB+\/IP+\u2009patients. The 21 LB+\u2009\/IP-myositis patients did not show differences in clinical features when compared with the NXP2-myositis patients and more frequently displayed multiple positivity at LB. Risk of developing cancer-associated myositis was similar between NXP2-positive and NXP2-negative myositis patients, either when detected by LB or IP. Protein-IP confirmed NXP2 antibodies in nearly 60% of sera positive for the same specificity with commercial assay. Double-positive cases rarely occurred in myositis patients with a clinical diagnosis other than dermatomyositis. Patients only positive by LB (LB+\/IP\u2212) did not display clinical features typical of NXP2. NXP2 positivity by LB should be confirmed by other methods in order to correctly diagnose and characterize patients affected by idiopathic inflammatory myositis.\n                  <\/jats:p>","DOI":"10.1007\/s12016-021-08920-y","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T10:02:48Z","timestamp":1643450568000},"page":"240-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations"],"prefix":"10.1007","volume":"63","author":[{"given":"Micaela","family":"Fredi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Barsotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Furini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Giudizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Isailovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Lazzaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Palterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Riccieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina","family":"Tampoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tripoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Zanframundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-6124","authenticated-orcid":false,"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FIRMA (Forum Italiano per la Ricerca nelle Malattie Autoimmuni)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"18","key":"8920_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372(18):1734\u20131747","journal-title":"N Engl J Med"},{"key":"8920_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB et al (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.001 (Epub 2019 Apr 13)","journal-title":"J Autoimmun"},{"issue":"12","key":"8920_CR3","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468 (Epub 2017 Oct 27)","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8920_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2018.56 (PMID: 29674612)","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl","key":"8920_CR5","first-page":"S139","volume":"40","author":"CV Oddis","year":"1997","unstructured":"Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M et al (1997) Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum 40(Suppl):S139","journal-title":"Arthritis Rheum"},{"key":"8920_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-020-05291-1","volume":"40","author":"L Li","year":"2021","unstructured":"Li L, Liu C, Cheng L, Yan S, Chen H, Li Y (2021) Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol 40:819\u2013822. https:\/\/doi.org\/10.1007\/s10067-020-05291-1 (Epub 2020 Jul 17)","journal-title":"Clin Rheumatol"},{"issue":"Suppl","key":"8920_CR7","first-page":"S787","volume":"56","author":"I Targoff","year":"2007","unstructured":"Targoff I, Trieu E, Levy-Neto M, Fertig N, Oddis C (2007) Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 56(Suppl):S787","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8920_CR8","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar3822","volume":"14","author":"A Ceribelli","year":"2012","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M et al (2012) Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis. Arthritis Res Ther 14(2):R97. https:\/\/doi.org\/10.1186\/ar3822","journal-title":"Arthritis Res Ther"},{"key":"8920_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","volume":"6","author":"EK Chan","year":"2015","unstructured":"Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo CW, Francescantonio PL et al (2015) Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014\u20132015. Front Immunol 6:412. https:\/\/doi.org\/10.3389\/fimmu.2015.00412 (PMID: 26347739; PMCID: PMC4542633)","journal-title":"Front Immunol"},{"issue":"2","key":"8920_CR10","first-page":"303","volume":"35","author":"M Fredi","year":"2017","unstructured":"Fredi M, Bartoli F, Cavazzana I, Ceribelli A, Carabellese N, Tincani A et al (2017) Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clin Exp Rheumatol 35(2):303\u2013308 (Epub 2016 Nov 14 PMID: 27908312)","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"8920_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) 69(12):1909\u20131914. https:\/\/doi.org\/10.1002\/acr.23210 (Epub 2017 Nov 2)","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8920_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clim.2018.11.008","volume":"198","author":"L Zhong","year":"2019","unstructured":"Zhong L, Yu Z, Song H (2019) Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts. Clin Immunol 198:11\u201318. https:\/\/doi.org\/10.1016\/j.clim.2018.11.008 (Epub 2018 Nov 13 PMID: 30445156)","journal-title":"Clin Immunol"},{"issue":"11","key":"8920_CR13","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L et al (2017) Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk. Arthritis Care Res 69(11):1771\u20131776. https:\/\/doi.org\/10.1002\/acr.23188","journal-title":"Arthritis Care Res"},{"issue":"10","key":"8920_CR14","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s10067-018-4216-x","volume":"37","author":"L Wang","year":"2018","unstructured":"Wang L, Huang L, Yang Y, Chen H, Liu Y, Liu K et al (2018) Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay. Clin Rheumatol 37(10):2731\u20132739. https:\/\/doi.org\/10.1007\/s10067-018-4216-x (Epub 2018 Jul 23)","journal-title":"Clin Rheumatol"},{"issue":"11","key":"8920_CR15","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum 65(11):2954\u20132962. https:\/\/doi.org\/10.1002\/art.38093 (PMID: 24037894; PMCID: PMC4073292)","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8920_CR16","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","volume":"49","author":"A Ghirardello","year":"2010","unstructured":"Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S et al (2010) Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 49(12):2370\u20132374. https:\/\/doi.org\/10.1093\/rheumatology\/keq281 (PMID: 20724434)","journal-title":"Rheumatology (Oxford)"},{"key":"8920_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","volume":"433","author":"I Cavazzana","year":"2016","unstructured":"Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N et al (2016) Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1\u20135. https:\/\/doi.org\/10.1016\/j.jim.2016.02.017 (Epub 2016 Feb 18 PMID: 26906088)","journal-title":"J Immunol Methods"},{"issue":"1","key":"8920_CR18","first-page":"176","volume":"35","author":"A Ghirardello","year":"2017","unstructured":"Ghirardello A, Bettio S, Bassi N, Gatto M, Beggio M, Lundberg I et al (2017) Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay. Clin Exp Rheumatol 35(1):176\u2013177 (Epub 2016 Sep 8 PMID: 27749219)","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"8920_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212709","volume":"77","author":"IE Lundberg","year":"2018","unstructured":"Lundberg IE, Tj\u00e4rnlund A (2018) Response to \u201c2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?\u201d by Malaviya. Ann Rheum Dis 77(11):e78. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212709 (Epub 2017 Dec 15 PMID: 29247124)","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8920_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212915","volume":"78","author":"JB Vulsteke","year":"2019","unstructured":"Vulsteke JB, De Langhe E, Claeys KG, Dillaerts D, Poesen K, Lenaerts J et al (2019) Detection of myositis-specific antibodies. Ann Rheum Dis 78(1):e7. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212915 (Epub 2018 Jan 25 PMID: 29371203)","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8920_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213320","volume":"78","author":"M Infantino","year":"2019","unstructured":"Infantino M, Manfredi M, Grossi V, Benucci M (2019) Detection of myositis-specific antibodies: additional notes. Ann Rheum Dis 78(4):e29. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213320 (Epub 2018 Mar 13 PMID: 29535123)","journal-title":"Ann Rheum Dis"},{"key":"8920_CR22","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","volume":"10","author":"M Mahler","year":"2019","unstructured":"Mahler M, Betteridge Z, Bentow C, Richards M, Seaman A, Chinoy H et al (2019) Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol 10:848. https:\/\/doi.org\/10.3389\/fimmu.2019.00848","journal-title":"Front Immunol"},{"issue":"6","key":"8920_CR23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","volume":"78","author":"F Espinosa-Ortega","year":"2019","unstructured":"Espinosa-Ortega F, Holmqvist M, Alexanderson H, Storfors H, Mimori T, Lundberg IE et al (2019) Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann Rheum Dis 78(6):858\u2013860. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214690 (Epub 2019 Feb 13 PMID: 30760469)","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8920_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215884","volume":"79","author":"I Cavazzana","year":"2019","unstructured":"Cavazzana I, Fredi M, Franceschini F (2019) Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance? Ann Rheum Dis 79(11):e152. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215884 (Epub 2019 Jul 15 PMID: 31308068)","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8920_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41927-020-00132-9","volume":"20","author":"F To","year":"2020","unstructured":"To F, Vent\u00edn-Rodr\u00edguez C, Elkhalifa S, Lilleker JB, Chinoy H (2020) Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatol 20(4):28. https:\/\/doi.org\/10.1186\/s41927-020-00132-9 (PMID: 32699830; PMCID: PMC7370419)","journal-title":"BMC Rheumatol"},{"issue":"6","key":"8920_CR26","first-page":"1048","volume":"37","author":"DF Fiorentino","year":"2019","unstructured":"Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L (2019) Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clin Exp Rheumatol 37(6):1048\u20131051 (Epub 2019 Jul 19)","journal-title":"Clin Exp Rheumatol"},{"key":"8920_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"8920_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1297-319X(03)00012-5","volume":"70","author":"A Imbert-Masseau","year":"2003","unstructured":"Imbert-Masseau A, Hamidou M, Agard C, Groulleau JY, Cherin P (2003) Antisynthetase syndrome. Joint Bone Spine 70:161\u2013168","journal-title":"Joint Bone Spine"},{"key":"8920_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0032-1329197","volume":"32","author":"MM Dimachkie","year":"2012","unstructured":"Dimachkie MM, Barohn RJ (2012) Inclusion body myositis. Semin Neurol 32:237\u2013245","journal-title":"Semin Neurol"},{"key":"8920_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W (2018) Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort The Netherlands 14\u201316 October 2016. Neuromuscul Disord 28:87\u201399","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"8920_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y et al (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259. https:\/\/doi.org\/10.1186\/s13075-017-1469-8","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"8920_CR32","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/art.22329","volume":"56","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC et al (2007) Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum 56(2):596\u2013604. https:\/\/doi.org\/10.1002\/art.22329","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8920_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223\u2013243. https:\/\/doi.org\/10.1097\/MD.0b013e31829d08f9","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"8920_CR34","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR et al (2014) Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 53(12):2204\u20132208. https:\/\/doi.org\/10.1093\/rheumatology\/keu259 (Epub 2014 Jul 1)","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8920_CR35","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE et al (2009) Autoantibodies to a 140-kD protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60(6):1807\u20131814. https:\/\/doi.org\/10.1002\/art.24547","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8920_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","volume":"15","author":"S Greenberg","year":"2019","unstructured":"Greenberg S (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15(5):257\u2013272. https:\/\/doi.org\/10.1038\/s41584-019-0186-x","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"8920_CR37","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3899\/jrheum.141443","volume":"42","author":"I Pinal-Fernandez","year":"2015","unstructured":"Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL (2015) The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42(8):1448\u20131454 (PMID: 26443871)","journal-title":"J Rheumatol"},{"issue":"5","key":"8920_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71(5):710\u2013713. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200697 (Epub 2012 Jan 17 PMID: 22258483)","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8920_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","volume":"36","author":"A Ceribelli","year":"2017","unstructured":"Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I et al (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36(2):469\u2013475. https:\/\/doi.org\/10.1007\/s10067-016-3453-0 (Epub 2016 Oct 20 PMID: 27761751)","journal-title":"Clin Rheumatol"},{"issue":"5","key":"8920_CR40","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1091\/mbc.e06-08-0747","volume":"18","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M et al (2007) Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 18(5):1701\u20131709. https:\/\/doi.org\/10.1091\/mbc.e06-08-0747 (Epub 2007 Mar 1)","journal-title":"Mol Biol Cell"},{"issue":"5","key":"8920_CR41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jcp.25665","volume":"232","author":"G Hong","year":"2017","unstructured":"Hong G, Qiu H, Wang C, Jadhav G, Wang H, Tickner J et al (2017) The emerging role of MORC family proteins in cancer development and bone homeostasis. J Cell Physiol 232(5):928\u2013934. https:\/\/doi.org\/10.1002\/jcp.25665 (Epub 2016 Nov 30 PMID: 27791268)","journal-title":"J Cell Physiol"},{"issue":"2","key":"8920_CR42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","volume":"57","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Mart\u00ednez MA, Milisenda JC et al (2018) Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford) 57(2):388\u2013396. https:\/\/doi.org\/10.1093\/rheumatology\/kex413","journal-title":"Rheumatology (Oxford)"},{"issue":"6167","key":"8920_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1126\/science.1246886","volume":"343","author":"CG Joseph","year":"2014","unstructured":"Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152\u2013157. https:\/\/doi.org\/10.1126\/science.1246886 (Epub 2013 Dec 5)","journal-title":"Science"},{"issue":"8","key":"8920_CR44","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","volume":"59","author":"SL Tansley","year":"2020","unstructured":"Tansley SL, Li D, Betteridge ZE, McHugh NJ (2020) The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology (Oxford) 59(8):2109\u20132114. https:\/\/doi.org\/10.1093\/rheumatology\/keaa021","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"8920_CR45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/rheumatology\/key451","volume":"58","author":"M Infantino","year":"2019","unstructured":"Infantino M, Tampoia M, Fabris M, Alessio MG, Previtali G, Pesce G et al (2019) Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis. Rheumatology (Oxford) 58(7):1239\u20131244. https:\/\/doi.org\/10.1093\/rheumatology\/key451 (PMID: 30726990)","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"8920_CR46","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/art.40491","volume":"70","author":"H Yang","year":"2018","unstructured":"Yang H, Lu X, Peng Q, Jiang W, Shi J, Zhang Y et al (2018) Differential clinical associations of anti-nuclear matrix protein 2 autoantibodies in patients with idiopathic inflammatory myopathies. Arthritis Rheumatol 70(8):1288\u20131297. https:\/\/doi.org\/10.1002\/art.40491 (Epub 2018 Jun 27 PMID: 29534337)","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08920-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08920-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08920-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:52:40Z","timestamp":1673509960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08920-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["8920"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08920-y","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"22 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study has been approved by local ethic committee (ASST-Spedali Civili of Brescia, Italy), protocol number: 3511.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Data were obtained from medical charts: every patient signed our institutional consent for the management of personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}